GENE ONLINE|News &
Opinion
Blog

2020-09-16| SpecialTechnology

Exploring RNA Splicing as a Potential New Drug Avenue for Parkinson’s Disease

by Tulip Chakraborty
Share To
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. Approximately 60,000 people get diagnosed with PD in the United States alone and around 10 million people live with this motor disorder.
With the aging population of the world increasing, this age-dependent neurodegenerative disease is a substantial socioeconomic burden. Further complicating the situation is the lack of disease-modifying therapy, while the treatments available can only take care of the symptoms.
RNA mis-splicing as a potential mechanism of neurodegeneration.
The study by Boussaad et al. demonstrated that a mutation in one of the disease-causing gene, DJ-1 leads to mis-splicing of DJ-1.

GO Prime with only $1.49 now

LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top